Chris Hill
Analyst · Bank of America
Thanks Larry. And as Larry previously stated, the company announced that for 2020, we would focus on strengthening our balance sheet by reducing debt and working towards improving our liquidity position. Excess free cash has been a focus towards reducing debt and for 2020, the company reduced net debt by approximately $49 million. Additionally, the company took steps in refinancing a portion of our long-term debt and on January 12th of 2021 issued $60 million in new senior notes through a private placement. These new senior notes have a five to seven year maturity and the proceeds were used exclusively to reduce outstanding debt on our credit facility. As a reminder, our bank credit facility is sized at $225 million and after reducing the outstanding balance with proceeds from issuing the new senior notes in January, the company has over $150 million of available borrowing capacity under the facility. At this time, I’ll also provide an update on our debt leverage ratio as this is one of the more restrictive financial covenants tied to our corporate debt. The maximum leverage ratio was currently limited to three times of our trailing 12 month EBITDA. At December 31, the company’s leverage ratio was a little over 2.8 as we continue to manage our debt levels down to remain compliant with our covenants. As the company has forecast financial performance over the past several quarters, we’d always forecast our leverage ratio to reach its peak in the fourth quarter of 2020 and first quarter of 2021. We continue to forecast the company will remain compliant with our financial covenants and with current expectations for 2021 and as we continue applying excess free cash towards reducing debt, we are forecasting our leverage ratio to begin decreasing in the second quarter of 2021. Before we review the financial performance for the quarter, the guidance we gave on our last call and past calls, specifically excludes the impact of any FX gains or losses and assumes an effective tax rate of 20%. So, accordingly, our discussion today excludes any foreign exchange gain or loss for current and prior periods. Additionally, the financial results for the fourth quarter of 2020 including non-cash adjustment of $11.9 million to reverse previously recognized stock compensation expense that was associated with revalued performance share awards that did not fully vest and were revalued. Additionally, ex items included charge of $700,000 associated with additional inventory write-downs and facility exit costs. These additional credits and charges have also been excluded from the discussion of our financial results. Now looking at the income statement. Revenue from continuing operations was $113.7 million in the fourth quarter, up approximately 8% from $105.4 million in the prior quarter. The U.S. land markets continued to gain momentum through the fourth quarter and we did not see the pronounced decrease that was experienced in the fourth quarter for the previous two years. Although COVID-19 disruptions continue to persist, activities did resume on longer cycle international projects which also had some revenue growth in the fourth quarter. For the full year of 2020, revenue was $487.3 million, a decrease of 27% from 2019 revenue of $668.2 million. Of this revenue, service revenue, which is more international was $89.2 million for the quarter, up over 3% sequentially from $86.3 million last quarter. As stated earlier, we had some improvement in activity levels on international projects, but also saw an improvement in U.S. markets for fluids analysis and well diagnostic services. Our network of laboratories across the globe have remained operational throughout the fourth quarter and although there has been a resurgence of the virus, and additional restrictions in some countries, we continue to operate as activities return to project well sites and our client facilities. Product sales, which is equally tied to North America and international activity was $24.6 million for the quarter, an increase of over 28% from $19.1 million last quarter. Product sales for the U.S. market were up 44% sequentially, while international product sales were up over 16% compared to the prior quarter. Moving on to cost of services, ex items for the quarter, are just below 76% of service revenue and considering the operational challenges created by COVID-19 have held in pretty nicely when compared to 74% last quarter. These operational challenges would often result in additional costs and operational inefficiencies for both us and our clients are expected to continue until the disruptions and restrictions associated with COVID begin to abate. Cost of services averaged 74% for the year, which is comparable to 2019, as significant cost reductions were implemented in 2020 to align with the more efficient and appropriately sized cost structure. Cost of sales, ex items in the fourth quarter was 86% of revenue and has improved for two consecutive quarters from 90% during those earlier quarters. Our announced cost reduction initiatives were completed in the third quarter and fully realized this quarter and as revenue levels improve, we would expect our margins to expand. G&A, ex items for the quarter was $7.6 million and $38.6 million for the full year, down from $8.9 million last quarter and down from $40.8 million for the full year of 2019. The decrease in G&A cost also reflects the cost reductions implemented by the company in 2020. Depreciation and amortization for the quarter was $4.8 million, down from $5.2 million last quarter, reflecting lower capital expenditures in 2020. For the full year of 2020, we capital expenditures were $11.9 million, down almost 50% from 2019 levels. For the full year, depreciation and amortization expense was $20.9 million, down about 7.5% from the $22.6 million last year. EBIT ex items for the quarter was $13 million, up from $12.3 million last quarter and given the current circumstances continues to represent best-in-class EBIT margin of over 11%. Our operating income for the quarter on a GAAP basis was $23.4 million. Full year 2020 EBIT, ex items was $56.6 million and generated margins of 11.6%. Income tax expense ex-items and using an effective tax rate of 20% for the quarter was $2 million. On a GAAP basis, the company recorded income tax expense of $6.5 million. The unusual events of 2020 which included adjustments recorded for impairment of goodwill that was substantially non-deductible have also skewed the company's effective tax rate for 2020. But now looking forward to 2021, we project the company’s effective tax rate to be approximately 20%. The effective tax rate will continue to be somewhat sensitive to the geographic mix of earnings across the globe and the impact of items that are discrete to each quarter. Income from continuing operations ex items for the quarter was $8.1 million, up 10% sequentially from $7.3 million last quarter. For the full year 2020, ex items, it was $35.3 million. GAAP income from continuing operations was $13.9 million for the fourth quarter of 2020 and a loss of $97.1 million for the full year. Earnings per diluted share from continuing operations, ex items was $0.18 for the quarter and $0.78 for the full year. GAAP earnings per diluted share from continuing operations was $0.31 for the quarter and a loss of $2.18 per share for the full year. Now we'll move on to the balance sheet. Receivables were $83.2 million and decreased a little over $2 million from prior quarter. Our DSOs for the fourth quarter were exceptional at 62 days, a substantial improvement from the 68 days last quarter and the lowest we have achieved in a quarter in the last six years. For the full year, DSOs were 69 days in comparable with 2019. Core Lab has always maintained great focus on managing our working capital and we will continue this tradition in maintaining one of the lowest DSOs for an international oilfield service company. We currently do not anticipate any significant changes in payment practices from our client base. Inventory finished the year at $38.1 million, down approximately $4.7 million from last quarter. The decrease is primarily due to improved completion activity in the U.S. land market, as well as our team’s efforts in 2020 to work with our suppliers. Inventory turns were at 2.2 times for the year and we anticipate inventory turns will continue to improve throughout 2021, in line with improved activity levels for the U.S. land. And now on to the liability side of the balance sheet. Our long-term debt, with $261 million at the end of 2020 in considering cash, a $14 million net debt was reduced to $247 million or a decrease of $4 million in the fourth quarter. Over the course of 2020, we reduced our net debt by $49 million from last year end. Our debt is comprised of our senior notes at $150 million, as well as $111 million outstanding under our bank revolving credit facility at December 31st. As stated earlier, the company issued $60 million in new notes in January 2021. These new notes were issued with a purpose of refinancing a portion of $75 million of senior notes maturing in September of 2021. The company will continue with our longer term strategy towards reducing debt and Core Lab’s debt leverage ratio. Now looking at cash flow. For the full year of 2020, cash flow from operating activities was $57.9 million, and after paying for $11.9 million of CapEx for the year, our free cash flow in 2020 was $49 million marking the 19th consecutive year in which the company has generated positive free cash flow. In the fourth quarter, cash flow from operating activities included $21 million of cash payments that are unique to this quarter. Included in the $21 million is a one-time employee post-retirement payment of $16 million that was associated with a distribution from the company’s employee deferred compensation plan and the employee’s employment agreement. Additionally, the fourth quarter includes a $5 million payment for our 2021 annual corporate insurance program which is prepaid to lower the annual premium cost. For many years, Core Lab has invested in company-owned life insurance policies as an investment vehicle to fund our employees deferred compensation plan. This is not an uncommon practice and these policies are often referred to as COLI. As intended, the cash surrender value of these COLI policies was accessed to help fund these payments and in the fourth quarter, the company converted $11.5 million of the cash surrender value to cash, which was used towards funding these payments. However, the cash received from the COLI policies is treated as an investing activity and therefore is not included in our cash from operations or free cash flow. As a result, for the fourth quarter, cash flow used in operating activities was $2.9 million and after paying for $3.3 million in CapEx, our free cash flow in Q4 was a negative $6.2 million. A couple more important points on this topic. As of December 31, 2020, our employee deferred compensation plan is fully funded to our investments in company-owned life insurance policies. Additionally, our forecast of future employee distributions from this plan are expected to be immaterial for any one calendar year or quarter. Now on to CapEx. For 2021, the company anticipates that its CapEx for the next couple of quarters will be at similar levels to recent quarters. However, as 2021 is expected to improve in the second half, we would also expect our capital expenditures to increase, but stay in line with historical levels while in a growth period. Core will continue our strict capital discipline and asset-light business model with capital expenditures primarily targeted at growth opportunities and initiatives. This also marks the 19th consecutive year Core Lab has generated positive free cash flow and we are projecting to continue generating positive free cash flow, as we look ahead to 2021 and beyond. We believe evaluating a company’s ability to generate free cash and free cash flow yield is an important metric for shareholders when comparing companies’ financial results, particularly for those shareholders to utilize discounted cash flow models to assess valuations. I will now turn it over Gwen for an update on our guidance and outlook.